These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 35776375)

  • 1. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
    Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
    Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
    Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
    ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine-associated gastrointestinal ulceration, haemorrhage, and obstruction: a pharmacovigilance analysis based on the FAERS.
    Wang Y; Meng L; Liu X
    Front Pharmacol; 2024; 15():1412938. PubMed ID: 38948471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac arrhythmias associated with anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
    Wang F; Xu G; Wu X
    Expert Opin Drug Saf; 2023; 22(11):1127-1132. PubMed ID: 37428255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
    Huang J; Meng L; Yang B; Sun S; Luo Z; Chen H
    Sci Rep; 2020 Mar; 10(1):4803. PubMed ID: 32179761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database.
    Zhou Z; Wang C; Ying L; Jin M; Zhang F; Shi D
    J Clin Pharm Ther; 2021 Aug; 46(4):1148-1154. PubMed ID: 33768534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase).
    Niimura T; Miyata K; Hamano H; Nounin Y; Unten H; Yoshino M; Mitsuboshi S; Aizawa F; Yagi K; Koyama T; Goda M; Kanda Y; Izawa-Ishizawa Y; Zamami Y; Ishizawa K
    Drug Saf; 2023 Jun; 46(6):545-552. PubMed ID: 37106270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study.
    Zhao M; Liu S; Xie R; Zhang J; Li J
    Expert Opin Drug Saf; 2023; 22(12):1309-1316. PubMed ID: 37551674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
    Sisi M; Fusaroli M; De Giglio A; Facchinetti F; Ardizzoni A; Raschi E; Gelsomino F
    Target Oncol; 2022 Jan; 17(1):43-51. PubMed ID: 35025076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboembolic Events Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System (FAERS) Database.
    Yang X; Yang B; Li D; Pan W; Tong Q; Wang L; Chen D; Fu C
    Clin Drug Investig; 2024 Mar; 44(3):199-207. PubMed ID: 38376794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system.
    Xiao Z; Cao J; Wu S; Zhou T; Li C; Duan J; Yang Z; Xu F
    CNS Neurosci Ther; 2024 Jul; 30(7):e14862. PubMed ID: 39009505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration Adverse Event Reporting System data.
    Yan Y; Wang L; Yuan Y; Xu J; Chen Y; Wu B
    Expert Opin Drug Saf; 2024 Jun; 23(6):771-776. PubMed ID: 37615268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
    Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
    Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.
    Yang Q; Wang J; Wang M; Zhang S; He QQ
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):64. PubMed ID: 39267168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data.
    Wei C; Liu Y; Jiang A; Wu B
    Int J Clin Pharm; 2022 Jun; 44(3):709-716. PubMed ID: 35364753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
    Zhao D; Long X; Zhou J; Wang J
    Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real-world study based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Zhao ZX; Yang TY; Wang YH; Zhang L; Li J; Su YW
    Br J Clin Pharmacol; 2024 Sep; 90(9):2166-2179. PubMed ID: 38831641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Rong L; Xie M; Jiang M; Qiu H; Kong L
    Br J Clin Pharmacol; 2024 Aug; 90(8):1816-1826. PubMed ID: 36702463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.